Bristol Myers Squibb and Hengrui Pharma have agreed to a broad global drug-discovery pact spanning 13 programs across oncology, hematology and immunology, with BMS paying $600 million upfront. The partners framed the arrangement as an effort to accelerate discovery through Hengrui’s R&D capabilities while using BMS for select assets and joint development. The deal structure also reflects the growing role of China-based R&D in global pipeline buildouts: Hengrui will hold exclusive rights in mainland China, Hong Kong and Macau, while BMS will retain rights for the rest of the world. Multiple assets are slated for advancement toward clinical entry, with the overall value potentially topping $15 billion depending on progress and commercial outcomes. For biotech companies watching deal dynamics, the transaction signals that mega-partnerships with sizable upfront consideration remain active even as companies prioritize reinvestment into earlier-stage programs. It also underscores Big Pharma’s continued focus on adding geographically complementary discovery capacity rather than relying only on internal R&D throughput. Separately, the same transaction has been reported as including a mix of Hengrui-sourced assets, BMS-sourced assets and jointly discovered candidates, positioning the agreement as both a portfolio expansion and a discovery platform collaboration.